Current Drugs for Friedreich Ataxia Show Little Benefit After One Year
A Cochrane meta-analysis of 8 RCTs finds most pharmacological treatments fail to improve ataxia scores, though upper limb dexterity may benefit.
Summary
A Cochrane review pooled data from eight randomized controlled trials (seven in meta-analysis, 574 participants total) testing drugs including idebenone, omaveloxolone, CoQ10 plus vitamin E, epoetin alpha, leriglitazone, and RT001 in people with Friedreich ataxia. After 12 months, pharmacological therapies showed little to no improvement in overall ataxia scores compared to placebo (moderate-certainty evidence). Unexpectedly, upper limb dexterity showed a probable moderate improvement across three studies. Effects on heart muscle thickness, daily living activities, and exercise capacity remained highly uncertain. Adverse events causing discontinuation were rare and similar between drug and placebo groups. Evidence quality ranged from very low to moderate, meaning current treatments cannot be confidently recommended for halting disease progression.
Detailed Summary
Friedreich ataxia is a rare inherited neurological disorder causing progressive loss of coordination, cardiomyopathy, and premature death in roughly 60% of patients from cardiac complications. Despite growing research interest, it remains unclear whether available pharmacological treatments meaningfully alter disease course over clinically relevant timeframes.
This updated Cochrane systematic review — the third update of a review first published in 2009 — searched global trial registries through February 2025 and included eight randomized controlled trials, seven of which contributed to meta-analysis enrolling 574 participants aged 8 to 70 years. Drugs evaluated included idebenone, omaveloxolone, CoQ10 plus vitamin E, epoetin alpha, leriglitazone, and RT001 (one trial of pioglitazone has not published results). Only trials lasting at least 12 months in genetically confirmed FRDA were eligible.
The headline finding is sobering: meta-analysis of seven studies showed pharmacological treatment probably makes little or no difference to ataxia rating scale scores after 12 months (SMD 0.02, 95% CI -0.23 to 0.26; moderate-certainty evidence). Effects on cardiac septal thickness, activities of daily living, and cardiopulmonary exercise capacity were all highly uncertain, based on very low-certainty evidence. One unexpected bright spot emerged — three studies demonstrated a probable moderate improvement in upper limb dexterity (SMD -0.42, 95% CI -0.73 to -0.11; moderate-certainty evidence), a finding the authors themselves describe as unexpected given the lack of effect on overall ataxia scores.
Safety data were reassuring but limited. Treatment-emergent adverse events leading to discontinuation or death were rare and did not differ significantly between drug and placebo groups, though the analysis covered only a subset of participants and may have missed infrequent serious events.
For clinicians managing FRDA patients, these results underscore that no current drug has convincingly demonstrated broad disease-modifying effects at one year. The modest dexterity signal may be meaningful for quality of life and deserves focused study. Larger, longer trials with standardized endpoints remain urgently needed.
Key Findings
- Pharmacological treatments showed little to no improvement in overall ataxia scores after 12 months (moderate-certainty evidence).
- Upper limb dexterity probably improved moderately with treatment across three studies (SMD -0.42, moderate-certainty).
- Effects on cardiac septal thickness, daily living, and exercise capacity were highly uncertain due to very low-quality evidence.
- Treatment-emergent adverse events causing discontinuation were rare and similar between drug and placebo groups.
- No curative or clearly disease-modifying pharmacological treatment for FRDA has been established at 12 months.
Methodology
This is a Cochrane systematic review and meta-analysis of eight RCTs (seven included in meta-analysis) involving 574 participants with genetically confirmed Friedreich ataxia, requiring a minimum 12-month treatment duration. Risk of bias was assessed using Cochrane RoB 2; evidence certainty was graded using GRADE. Outcomes included validated ataxia scales, cardiac imaging, activities of daily living, upper limb dexterity, and cardiopulmonary exercise testing.
Study Limitations
The review is based on only eight small-to-moderate RCTs (total 574 participants), limiting statistical power to detect modest but clinically meaningful effects. Evidence certainty was very low for most outcomes due to imprecision, inconsistency, and suspected publication bias. This summary is based on the abstract only, as the full review text was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.